Measurement of the free form of TFPI antigen in hyperlipidemia: Relationship between free and endothelial cell-associated forms of TFPI

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 6, 1996, Pages 802-808

  Kokawa, Toshinori ^a   Enjyoji, Kei Ichi ^a   Kumeda, Kousuke ^c   Kamikubo, Yu Ichi ^c   Harada Shiba, Mariko ^a   Koh, Hideki ^b   Tsushima, Motoo ^b   Yamamoto, Akira ^a   Kato, Hisao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Div Atherosclerosis Metab Clin N   (Japan)

^c The Chemo Sera Therapeutic Research Institute (KAKETSUKEN)   (Japan)

Author keywords

endothelial cell; enzyme immunoassay; hyperlipidemia; plasmapheresis; tissue factor pathway inhibitor

Indexed keywords

ANTIGEN; HEPARIN; MONOCLONAL ANTIBODY; PROTEINASE; THROMBOPLASTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; HYPERLIPIDEMIA; MEASUREMENT; PLASMAPHERESIS; PRIORITY JOURNAL;

EID: 0030012444     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.6.802     Document Type: Article

References (26)

1. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263: 6001-6004.
2. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the FVIIa-TF complex, also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71:335-343.
3. Girard JJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989;338:518-520.
4. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SD, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoproteinassociated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA. 1990;87: 8869-8873.
5. Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem. 1992;111: 681-687.
6. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988;50: 803-813.
7. Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein associated inhibitor. Blood. 1991;78:394-400.
8. Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res. 1990;59:651-656.
9. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 1987;47:389-400.
10. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagulation Fibrinol. 1991;2:713-721.
11. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;31:18832-18837.
12. Kokawa T, Abumiya T, Kimura T, Harada MS, Koh H, Tsushima M, Yamamoto A, Kato H. Tissue factor pathway inhibitor activity in human plasma: measurement of lipoprotein-associated and free form in hyperlipidemia. Arterioscler Thromb Vase Biol. 1995;15: 504-510.
13. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free form of TFPI but not lipoprotein-associated forms in plasma. J Biochem. 1995;118: 178-182.
14. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
15. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagulation Fibrinol. 1994;5:819-823.
16. Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and low molecular weight heparin. Thromb Res. 1995;77:175-185.
17. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagata S, Minami N, Nakano T Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1995;73: 10-14.
18. Leurs PB, Oerle RV, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes. 1995;44:80-84.
19. Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection increased response in cancer patients. Thromb Res. 1990;59:651-656.
20. Abumiya T, Nakamura S, Takenaka A, Takenaka O, Yoshikuni Y, Miyamoto S, Kimura T, Enjyoji K, Kato H. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb. 1994; 14:483-488.
21. Hansen J-B, Huesby KR, Huesby N-E, Sandset PM, Hanssen T-A, Nordoy A. Effect of cholesterol lowering on intravascular potential in type II hyperlipoproteinemia. Arteriosder Thromb Vase Biol. 1995;15:879-885.
22. Enjyoji K, Miyata T. Kamikubo Y, Kato H. Effect of heparin on the inhibition of Factor Xa by tissue factor pathway inhibitor: a segment Gly212-Phe243 of the third Kunitz domain is a heparin binding site. Biochemistry. 1995;34:5725-5735.
23. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ. Structural requirement for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagulation Fibrinol. 1993;4:661-669.
24. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagulation Fibrinol. 1994;5:551-559.
25. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with HMG Co A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb. 1991;11:138-145.
26. Hansen J-B, Huesby N-E, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14:223-229.